Literature DB >> 19651364

Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.

Shihai Huang1, Brian Erickson, Ning Tang, Wai-Bing Mak, John Salituro, John Robinson, Klara Abravaya.   

Abstract

BACKGROUND: Abbott RealTime High Risk (HR) HPV is a recently developed test for the detection of 14 high-risk oncogenic HPV types combined with the ability to concurrently identify genotypes 16 and 18.
OBJECTIVES: The clinical performance of the Abbott RealTime HR HPV test was evaluated in comparison with the Hybrid Capture 2 (HC2) test for the detection of cervical intraepithelial neoplasia 2 or worse (CIN2+). The relative accuracy of the Abbott RealTime HR HPV to detect high-risk HPV was also determined. STUDY
DESIGN: Cervical specimens were collected from 702 patients with abnormal cytology who were referred for colposcopy, and were tested with liquid based cytology (LBC), Abbott RealTime HR HPV and HC2. Genotyping was done using the Linear Array (LA) method. Histological assessment was used as the gold standard for disease status. Clinical performance for detection of disease was evaluated for Abbott RealTime HR HPV in comparison with HC2 in the overall population and in each cytological grade. The relative accuracy for detection of high-risk HPV was assessed by concordance between the two tests and based on LA genotyping. RESULTS AND
CONCLUSIONS: The Abbott RealTime HR HPV showed similar clinical performance for detection of CIN2+ when compared with HC2, for both the overall population and those with a cytological grade of atypical squamous cells of undetermined significance (ASC-US). The accuracy for detection of high-risk HPV was significantly higher with Abbott RealTime HR HPV than with HC2.

Entities:  

Mesh:

Year:  2009        PMID: 19651364     DOI: 10.1016/S1386-6532(09)70004-6

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  9 in total

1.  Oral and oropharyngeal papillomas are not associated with high-risk human papillomavirus infection.

Authors:  Miroslaw Snietura; Roman Lamch; Agnieszka Kopec; Dariusz Waniczek; Wirginia Likus; Dariusz Lange; Jaroslaw Markowski
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-21       Impact factor: 2.503

2.  Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.

Authors:  Samuel Ratnam; Francois Coutlee; Dan Fontaine; James Bentley; Nicholas Escott; Prafull Ghatage; Veeresh Gadag; Glen Holloway; Elias Bartellas; Nick Kum; Christopher Giede; Adrian Lear
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

3.  Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.

Authors:  F M Carozzi; E Burroni; S Bisanzi; D Puliti; M Confortini; P Giorgi Rossi; C Sani; A Scalisi; F Chini
Journal:  J Clin Microbiol       Date:  2011-02-16       Impact factor: 5.948

4.  Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA.

Authors:  Yongjung Park; Eunhee Lee; Jonghyeon Choi; Seri Jeong; Hyon-Suk Kim
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

5.  Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.

Authors:  Mario Poljak; Anja Ostrbenk; Katja Seme; Veronika Ucakar; Peter Hillemanns; Eda Vrtacnik Bokal; Nina Jancar; Irena Klavs
Journal:  J Clin Microbiol       Date:  2011-03-23       Impact factor: 5.948

6.  Performance of a New HPV Cervi-Collect Collection and Transportation Kit.

Authors:  M Chernesky; S Huang; D Jang; B Erickson; J Salituro; H Engel; J Gilchrist; P Neuscheler; W B Mak; K Abravaya
Journal:  J Oncol       Date:  2011-11-14       Impact factor: 4.375

7.  Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens.

Authors:  Thomas Iftner; Lisa Wang; Angelika Iftner; Barbara Holz; Juliane Haedicke-Jarboui; Nathalie Iftner; Reinhard von Wasielewski; Peter Martus; Gerd Boehmer
Journal:  BMC Infect Dis       Date:  2016-11-11       Impact factor: 3.090

8.  Significance of "Not Detected but Amplified" Results by Real-Time PCR Method for HPV DNA Detection.

Authors:  Taek Soo Kim; Mi Suk Lim; Yun Ji Hong; Sang Mee Hwang; Kyoung Un Park; Junghan Song; Eui-Chong Kim
Journal:  Biomed Res Int       Date:  2016-12-21       Impact factor: 3.411

9.  Tumor-suppressor gene SOX1 is a methylation-specific expression gene in cervical adenocarcinoma.

Authors:  Min Yuan; Lili Yao; Guzhalinuer Abulizi
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.